ZENATANE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZENATANE (ZENATANE).
Isotretinoin (13-cis-retinoic acid) reduces sebaceous gland size and inhibits sebum production by binding to nuclear retinoic acid receptors (RARs and RXRs), altering gene expression involved in cell differentiation and apoptosis.
| Metabolism | Hepatic metabolism primarily via CYP2C9, CYP2C8, and CYP3A4, with major metabolites including 4-oxo-isotretinoin and tretinoin. |
| Excretion | Primarily renal excretion as unchanged drug (60-70%) and glucuronide conjugates (10-20%). Fecal elimination accounts for 10-15% via biliary secretion. |
| Half-life | Terminal elimination half-life is 16-22 hours (mean 19 hours) in adults. Steady-state achieved in 3-5 days. Half-life may be prolonged up to 40 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 90-95% bound to serum albumin (mainly albumin, some to alpha-1-acid glycoprotein). Binding is saturable with hypoalbuminemia or uremia. |
| Volume of Distribution | Vd = 0.6-0.8 L/kg in normal-weight adults (approx 40-60 L/70 kg). Higher Vd in obesity (0.8-1.2 L/kg) due to lipophilicity, indicating extensive distribution into tissues (e.g., adipose, brain). |
| Bioavailability | Oral: 85-100% (mean 95%) for immediate-release tablets. Food may delay absorption but does not significantly affect extent. Extended-release: 80-90% relative to immediate-release. |
| Onset of Action | Oral: 30-60 minutes for detectable serum levels; clinical effect (e.g., seizure control) within 30 minutes to 2 hours. Intravenous: 5-15 minutes for peak concentrations; clinical effect within 15-30 minutes. |
| Duration of Action | Oral: Anticonvulsant effect lasts 6-12 hours with immediate-release formulations; extended-release may provide 12-24 hours. Intravenous: Duration 4-6 hours due to rapid redistribution. |
0.5 mg/kg orally once daily, titrated up to 1 mg/kg/day based on response; maximum 2 mg/kg/day.
| Dosage form | CAPSULE |
| Renal impairment | GFR 30-89 mL/min: reduce dose by 25%; GFR 15-29 mL/min: reduce dose by 50%; GFR <15 mL/min: contraindicated. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated. |
| Pediatric use | 0.25 mg/kg orally once daily, increase by 0.25 mg/kg every 2 weeks to a maximum of 1 mg/kg/day; not recommended for children <2 years. |
| Geriatric use | Initiate at 0.25 mg/kg/day; monitor renal function and adjust accordingly; avoid in frail elderly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ZENATANE (ZENATANE).
| Breastfeeding | Contraindicated. Isotretinoin is secreted in human milk; M/P ratio not established. Potential for severe adverse effects in nursing infant. Breastfeeding not recommended. |
| Teratogenic Risk | First trimester: Major congenital malformations (CNS, cardiovascular, facial) in up to 25-30% of exposed fetuses; spontaneous abortion risk increased. Second/third trimester: Central nervous system abnormalities, intellectual disability, preterm birth, low birth weight. Contraindicated in pregnancy (Pregnancy Category X). |
■ FDA Black Box Warning
Isotretinoin is teratogenic and is contraindicated in pregnancy. It must not be used by female patients who are or may become pregnant. There is an extremely high risk of severe birth defects if pregnancy occurs during treatment.
| Common Effects | Dizziness Nausea Vomiting Constipation Sleepiness Abnormality of voluntary movements |
| Serious Effects |
Pregnancy or possibility of pregnancy; women of childbearing potential not using reliable contraception; hypersensitivity to isotretinoin or parabens; concomitant use with tetracyclines (risk of pseudotumor cerebri); elevated blood lipid levels; pancreatitis history.
| Precautions | Risk of severe depression, psychosis, suicidal ideation; pseudotumor cerebri; pancreatitis (fatal cases); hepatotoxicity; skeletal hyperostosis; premature epiphyseal closure; lipid abnormalities; inflammatory bowel disease; photosensitivity; hearing impairment; ophthalmic effects. |
Loading safety data…
| Fetal Monitoring |
| Pregnancy test (serum β-hCG) before initiation, monthly during therapy, and 1 month after discontinuation. Baseline liver function tests, serum lipids, CBC; repeat monthly for first 2 months then every 3 months. Monitor for depression/psychiatric symptoms. Fetal ultrasound if pregnancy occurs. |
| Fertility Effects | No known impairment of fertility in males or females based on limited data. Reversible alterations in spermatogenesis have been reported in some studies but not consistently. No effect on female fertility. |